Arima Genomics
Arima Genomics is a private cancer diagnostics company that uses proprietary Hi-C sequencing technology to detect gene fusions, rearrangements, and structural variants from FFPE samples, serving oncologists, biopharma, and academic researchers through its Aventa clinical tests and Arima Discovery research platform.
- Company typePrivate
- Founded2015
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Arima Genomics does
Arima Genomics is a private biotechnology company founded in 2015 and headquartered in Carlsbad, California, that develops DNA-based cancer diagnostics built on a proprietary Hi-C sequencing platform capable of capturing the three-dimensional structure of the cancer genome from routine formalin-fixed paraffin-embedded (FFPE) tissue samples. Its commercial offering is the Aventa clinical testing brand, which comprises Aventa FusionPlus for solid tumors (launched 2023) and Aventa Lymphoma for B- and T-cell lymphomas (broadly launched September 2025), the latter reporting on 417 genes and granted AMA PLA code 0592U. The company operates a CLIA-certified clinical testing laboratory in Orlando, Florida, providing end-to-end specimen logistics with results typically returned in 10 business days, and sells research-use Hi-C kits globally through the Arima Discovery platform.
Arima serves three primary customer segments: oncologists and cancer centers requiring comprehensive genomic profiling for diagnosis and therapy selection; biopharma companies seeking biomarker-defined patient populations for targeted therapy development; and academic researchers studying 3D genome organization through collaborations that drive peer-reviewed publications in journals including Cell Genomics, Genes, and the Journal of Molecular Diagnostics. The company generates revenue through professional-services clinical testing fees, one-time research product licenses, and biopharma partnership arrangements, with no publicly disclosed pricing.
Recent evidence positions Aventa tests as superior to conventional FISH and RNA-seq for structural variant detection, including a 159-patient DLBCL study showing Hi-C detected 97% of clinically relevant biomarker rearrangements versus 76% for FISH, and a finding that Hi-C identified oncogene rearrangements in 37% of driver-negative NSCLC tumors. The company has raised approximately $29 million total in venture funding across a $7M Series B (March 2022) and a $22M Series C led by Illumina Ventures (June 2025), and is led by CEO Tom Willis, PhD, with founder Sid Selvaraj serving as President and COO. Notable institutional partnerships include Fox Chase Cancer Center — the first NCI-designated Comprehensive Cancer Center to implement Arima's technology as standard protocol — alongside multi-center studies with Johns Hopkins, Duke, University of Michigan, and NYU.
Arima Genomics firmographics
Firmographics- Name
- Arima Genomics
- Legal name
- Arima Genomics, Inc.
- Website
- https://arimagenomics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Arima Genomics is a private cancer diagnostics company that uses proprietary Hi-C sequencing technology to detect gene fusions, rearrangements, and structural variants from FFPE samples, serving oncologists, biopharma, and academic researchers through its Aventa clinical tests and Arima Discovery research platform.
- Ownership category
- akta.pro rank
Arima Genomics industry classification
Industry- Product category
- Cancer Genomics Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Epigenomics & Chromatin Profiling Services (HLAGANAF)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Arima Genomics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Arima Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Testing Services: CLIA-certified laboratory providing Aventa clinical tests (Aventa FusionPlus for solid tumors and Aventa Lymphoma for lymphoma) to oncologists. Results typically returned in 10 business days with end-to-end specimen logistics.
- Research Products: Advanced kits and informatics supporting discovery-stage researchers worldwide through the Arima Discovery platform.
- Biopharma Partnerships: Partnerships with biopharma teams to connect structural cancer drivers to therapeutic opportunity, identifying biomarker-defined patient populations and informing development strategy.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Arima Genomics product offering
Product offeringCore offering
Arima Genomics develops and commercializes a proprietary Hi-C sequencing platform that captures the 3D structure of cancer genomes from routine FFPE tissue, operationalized through the Aventa clinical testing brand (Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas) processed in a CLIA-certified lab. The company also distributes research-grade Hi-C kits and informatics via the Arima Discovery platform and runs biopharma partnerships that link structural cancer drivers to therapeutic and biomarker strategies.
Product overview
Arima Genomics offers the Aventa clinical testing platform built on proprietary Hi-C sequencing technology. The platform consists of two clinical tests: Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas. Both tests leverage genome-wide Hi-C sequencing to detect gene fusions, rearrangements, and structural variants from routine FFPE samples that conventional methods like FISH may miss or incompletely characterize. The platform powers clinical diagnostics, biopharma partnerships, and translational science research.
Differentiator
Problem solved
Functional benefit
Brands
- Aventa: Clinical testing brand from Arima Genomics, bringing Hi-C sequencing technology into cancer care through tests designed for routine FFPE samples. Includes Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas.
- Aventa FusionPlus
- Aventa Lymphoma
Products and services
- Aventa FusionPlus Clinical test for solid tumors that detects clinically relevant fusions and rearrangements genome-wide using Hi-C sequencing from routine FFPE samples, supporting diagnosis and therapy selection for oncologists and cancer centers.
- Aventa Lymphoma First whole-genome NGS-based clinical test for gene fusion and rearrangement detection in B- and T-cell lymphomas, reporting on 417 genes from routine FFPE specimens; intended for oncologists and cancer centers for diagnosis, classification, prognosis, and treatment planning.
- Arima Discovery Research Kits Research-grade Hi-C kits and informatics sold through the Arima Discovery online storefront to discovery-stage researchers worldwide for studying 3D genome organization and cancer-driving structural mechanisms from FFPE samples.
Quantifiable outcome
- Hi-C detected 97% of clinically relevant biomarker rearrangements vs. 76% for standard FISH in DLBCL cohort of 159 patients
- +3 more outcomes
Companies that use Arima Genomics
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Arima Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Arima Genomics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- University of MichigancoreCollaborated on Cell Genomics publication demonstrating FFPE-compatible Hi-C can identify clinically relevant rearrangements not captured by routine testing across 44 archival FFPE biopsies.
- New York University (NYU)coreCollaborated on Cell Genomics publication demonstrating FFPE-compatible Hi-C can identify clinically relevant rearrangements not captured by routine testing across multiple lymphoid malignancies.
- Fox Chase Cancer CentercorePartnership makes Fox Chase the first NCI-designated Comprehensive Cancer Center to implement clinical testing using Arima's 3D-genomics technology as part of standard protocol for multiple tumor types. The collaboration integrates clinical testing and research at scale, enabling new discoveries through analysis of de-identified patient response data for lymphoma and sarcoma diagnostics.
- Duke UniversitycoreMulti-center study involving 159 DLBCL patients demonstrating Hi-C sequencing detected additional clinically relevant rearrangements that routine FISH panels missed, with superior performance for key biomarkers.
- Johns Hopkins UniversitycoreCollaborative study published in Genes journal showing Aventa Lymphoma test clarifies ambiguous FISH results and uncovers additional genetic rearrangements in B-cell lymphoma cases, demonstrating impact on diagnosis and treatment decisions.
- VelseraminorPartnership to enable broad adoption of Arima Genomics' technology in clinical labs.
- Protean BiodiagnosticsminorPartnership to facilitate clinician ordering of a 3D genomics-based lab-developed test for detection of gene fusions across cancer sample types.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Arima Genomics competitors and assessment
Company assessmentDirect peers
- Personalis: Clinical NGS lab offering NeXT Personal (tumor + immuno-oncology) with deep structural-variant and tumor-informed MRD capabilities. Closely comparable in size, clinical-cancer focus, and emphasis on detecting alterations missed by standard panels.
- Phase Genomics: Hi-C and proximity-ligation genomics company focused on chromosome conformation and structural-variant detection for research and clinical applications. Closest pure technology peer to Arima, operating primarily in the research market with overlapping Hi-C platform approach.
- Bionano Genomics: Optical genome mapping platform (Saphyr/Irys) for structural-variant detection in cancer and constitutional disorders. Direct technology competitor for structural-variant and rearrangement detection, though using imaging rather than Hi-C chemistry.
- Caris Life Sciences: Operates a CLIA-certified lab offering MI Profile and other whole-transcriptome/whole-exome cancer tests targeting oncologists and biopharma. Closely comparable business model (CLIA lab + biopharma partnerships + clinical evidence-driven GTM) and competes for the same cancer-center customers as Arima.
Broad incumbents
- Tempus Labs: AI-enabled precision medicine company offering NGS profiling (Tempus xT), liquid biopsy, and biopharma data services. Broader portfolio than Arima but directly competes for oncologist ordering, biopharma CDx deals, and payor contracts.
- Foundation Medicine: Roche-owned leader in comprehensive NGS-based cancer profiling (FoundationOne CDx/HDx). Direct competitor in clinical cancer genomics with established payer coverage, broad oncologist adoption, and FDA-approved CDx claims — but does not specialize in 3D-genome structural-variant detection like Arima.
- NeoGenomics: Public clinical cancer genomics lab offering comprehensive solid-tumor and hematologic NGS panels (including Lymphoma Profile). Larger scale and broader menu than Arima but targets the same oncologist customer base with overlapping biomarker testing.
- Resolution Bioscience (Agilent): Acquired by Agilent, offers ctDNA and NGS-based liquid-biopsy cancer profiling. Now part of Agilent's broader diagnostics portfolio; competes with Arima in liquid-biopsy-adjacent oncology applications and shares Agilent's investment history with Arima (Agilent co-invested in 2020 round).
Emerging players
- Strata Oncology: Precision oncology company offering tumor profiling (Strata NGS) and clinical-trial matching for oncologists. Similar enterprise sales motion to cancer centers and biopharma, though narrower test menu and earlier commercial stage than Arima.
- Pillar Biosciences: Clinical NGS panel developer offering targeted cancer profiling kits (including SLIMamp/PIK3CA panels) to clinical labs. Comparable in scale and clinical-cancer focus, though Arima is whole-genome/structural-variant while Pillar is targeted-panel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Arima Genomics social profiles
Digital presenceArima Genomics compliance and trust
Trust signalCompliance1 record
Arima Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arima Genomics leadership team
Management profileNumber of profiles
Profiles8 records
Arima Genomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arima Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arima Genomics
What does Arima Genomics do?
Arima Genomics develops and commercializes a proprietary Hi-C sequencing platform that captures the 3D structure of cancer genomes from routine FFPE tissue, operationalized through the Aventa clinical testing brand (Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas) processed in a CLIA-certified lab. The company also distributes research-grade Hi-C kits and informatics via the Arima Discovery platform and runs biopharma partnerships that link structural cancer drivers to therapeutic and biomarker strategies.
Is Arima Genomics a public or private company?
Arima Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Arima Genomics founded?
Arima Genomics was founded in 2015. It employs 11 to 50 people.
Where is Arima Genomics based?
Arima Genomics is headquartered in San Diego, United States, in the North America region.
How does Arima Genomics make money?
Three revenue lines are on record. Clinical Testing Services are the primary driver. The others are research Products and biopharma Partnerships.
Who are Arima Genomics's main competitors?
Direct peers on record are Personalis, Phase Genomics, Bionano Genomics and Caris Life Sciences. Broad incumbents are Tempus Labs, Foundation Medicine, NeoGenomics and Resolution Bioscience (Agilent). Emerging players are Strata Oncology and Pillar Biosciences.
Does Arima Genomics have an API?
No public API is recorded for Arima Genomics.
What industry is Arima Genomics in?
Arima Genomics's product category is Cancer Genomics Diagnostics. Its primary akta.pro industry code is HLAGANAF, Epigenomics & Chromatin Profiling Services, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 541714 and its SIC code is 2835.